NCT03778671View on ClinicalTrials.gov

Dexmedetomidine Versus Fentanyl Added to Levobupivacaine for Transversus Abdominis Plane (TAP) Block

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

November 1, 2019

Study Completion Date

December 1, 2019

Conditions
Transversus Abdominis Block
Interventions
DRUG

Levobupivacaine

Patients will receive Levobupivacaine 5%

DRUG

Dexmedetomidine Injection [Precedex]

Patients will receive Levobupivacaine 5% + 1 µg/kg dexmedetomedine

DRUG

fentanyl

Patients will receive Levobupivacaine 5% + 1 µg/kg fentanyl

Trial Locations (1)

Unknown

Assiut governorate, Asyut

All Listed Sponsors
lead

Assiut University

OTHER

NCT03778671 - Dexmedetomidine Versus Fentanyl Added to Levobupivacaine for Transversus Abdominis Plane (TAP) Block | Biotech Hunter | Biotech Hunter